Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations study located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://andyr962qeq4.blogpixi.com/profile